LEADER 00000cam  2200661 i 4500 
001    ocn894626407 
003    OCoLC 
005    20170927053355.7 
006    m     o  d         
007    cr cn||||||||| 
008    140829s2012    enka    obt   000 0 eng   
016 7  101640337|2DNLM 
019    847596904|a867483646 
020    9780833079558 
020    0833079557 
027    RAND/TR-1213-EC 
035    (OCoLC)894626407|z(OCoLC)847596904|z(OCoLC)867483646 
037    22573/ctt36t6wd|bJSTOR 
040    NLM|beng|erda|epn|cNLM|dRSM|dJSTOR|dOCLCF|dYDXCP|dTEF
       |dOCLCQ 
042    pcc 
043    e------ 
049    CKEA 
050  4 RA399.5|b.E9 2012 
060  4 WT 500 
082 04 362.1|223 
100 1  Nolte, Ellen,|eauthor. 
245 10 Evaluating chronic disease management :|brecommendations 
       for funders and users /|cEllen Nolte [and 19 others] ; 
       prepared for the European Commission on behalf of the 
       DISMEVAL Consortium. 
264  1 Santa Monica, CA :|bRAND Corporation,|c2012. 
300    1 online resource (1 PDF file (xv, 85 pages)) :
       |billustrations. 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
490 1  Technical report ;|vTR-1213-EC 
500    Title from PDF title page. 
504    Includes bibliographical references. 
505 0  Introduction -- The context for evaluating chronic disease
       management -- Methods and metrics for evaluation: 
       experiences from the DISMEVAL project -- Practical 
       considerations for evaluation -- Challenges and lessons 
       learned -- Going forward: Conclusions and further research
       -- Appendix A: Summary overview of six DISMEVAL work 
       packages on disease management evaluation methods and 
       metrics -- Appendix B: Evaluation measures for disease 
       management (DM) interventions. 
520 3  The report forms part of the DISMEVAL project, funded 
       under the European Commission's 7th Framework Programme. 
       It is targeted at policymakers, programme operators and 
       researchers, explaining choices, options and trade-offs 
       for the evaluation of disease management based on analyses
       undertaken within the project. Many of the issues 
       discussed can be seen to apply to any evaluation of 
       complex interventions in healthcare. However, there are 
       specific concerns around evaluation design and metrics 
       that are of relevance to the evaluation of disease 
       management in particular and that are examined in the 
       report. These include (i) the context for evaluating 
       disease management, exploring the reasons for undertaking 
       evaluation in the first place and explaining some of the 
       underlying principles for doing so; (ii) the methods and 
       metrics for evaluating disease management, focusing 
       specifically on themes that have emerged as being 
       pertinent to work carried out within the DISMEVAL project;
       (iii) practical considerations for disease management 
       evaluation, based on experience of work undertaken in 
       DISMEVAL; and (v) the broader challenges and lessons 
       learned that may be relevant for policymakers, funders and
       practitioners interested in the use and usefulness of 
       disease management evaluation more generally. This 
       publication provides a major resource to guide the 
       evaluation of disease management interventions in European
       settings and so contributes to strengthening the evidence-
       base required to inform the selection of efficient and 
       effective interventions to address the growing burden of 
       chronic disease in Europe. 
538    Mode of access: internet via WWW.|5CStmoR 
588 0  Version viewed Oct. 20, 2014. 
610 20 DISMEVAL Project. 
650  0 Disease management|zEurope. 
650  7 Disease management.|2fast|0(OCoLC)fst00895152 
650 12 Chronic Disease|xeconomics. 
650 12 Chronic Disease|xtherapy. 
650 22 Cost of Illness. 
650 22 Evidence-Based Medicine. 
650 22 Treatment Outcome. 
651  7 Europe.|2fast|0(OCoLC)fst01245064 
655  2 Evaluation Studies. 
655  2 Technical Report. 
710 2  RAND Europe,|eissuing body. 
710 2  DISMEVAL Consortium,|eissuing body. 
830  0 Technical report (Rand Corporation) ;|vTR-1213-EC. 
914    ocn894626407 
994    92|bCKE